The key is to get care from CML experts — like the physicians at Fred Hutchinson Cancer Center — who know the complex factors that go into choosing the right treatments for you at the right time. Our ...

When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic ...

You may also hear your doctor call it chronic myeloid leukemia. It's the same disease, just a different name. With treatment, you may go into what's called "remission." For most people ...

Researchers have identified an approach to enhance the activity of a new anti-cancer agent that has already shown impressive efficacy in the treatment of chronic myelogenous leukemia Virginia ...

They will discuss the benefits and the possible side effects with you. The aim of treatment is to put your CML into remission. Remission means there are no signs of CML in your blood. The doctors ...

Teacher and CML patient Jen joins Dr. James Dugan to share how finding the right treatment changed her life—and what other ...

Typically, people whose CML is in the chronic phase respond well to standard treatments. People in this phase typically experience fatigue, shortness of breath, bone pain, infections, and bleeding.

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

At Fred Hutch Cancer Center, our CML experts understand the complex factors that go into planning the right approach for each patient. This includes knowing which treatments match your needs and goals ...

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid ...

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...